Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.47 |
| ▸ | PPARA | Q07869 | 13/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3976202 | 0.89 | PPARG (0.51) | PPARGPPARAPPARDALOX5 | |
| SCHEMBL11993021 | 0.89 | PPARG (0.51) | PPARGPPARAPPARDALOX5 | |
| SCHEMBL3973024 | 0.86 | PPARG (0.46) | PPARGPPARAPPARDALOX5 | |
| SCHEMBL6904181 | 0.83 | PTPN1 (0.38) | PPARGPPARAPPARD | |
| SCHEMBL6903473 | 0.82 | PPARG (0.44) | PPARGPPARAPPARD | |
| SCHEMBL11992997 | 0.80 | PPARG (0.43) | PPARGPPARA | |
| SCHEMBL16712021 | 0.77 | PPARG (0.47) | PPARGPPARA | |
| SCHEMBL3976050 | 0.77 | LMNA (0.46) | PPARGPPARA | |
| SCHEMBL3973311 | 0.76 | PPARG (0.54) | PPARGPPARA | |
| SCHEMBL3967738 | 0.76 | PPARG (0.62) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491747-B2 | 4-(Arylthio)- or (4-heteroarylthio)butyric acid derivatives that may be used in the treatment of dyslipidaemia, atherosclerosis and diabetes | MERCK PATENT GMBH (DE) | 2009-02-17 | — | — | US | disclosed |
| US-20050020651-A1 | Butyric acid derivatives | MERCK PATENT GMBH (DE) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020651-A1 | Butyric acid derivatives | GPR119, DBI, GABRB1 | PPARG 492/4885PPARA 425/4885PPARD 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.